Biochemical and Biophysical Research Communications
Regular ArticleEvidence for a Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine A Transport
Abstract
The characteristics of cyclosporin A (CsA) transport across Caco-2 monolayers were investigated. CsA (0.25 - 5.0 μM) was transported in a time and concentration dependent manner. The total amount of apical (AP) to basolateral (BL) transport was non-linearly related to CsA concentration from 0.25 to 1 μM and was linear from about 1 to 5 μM. Average permeability coefficient (Papp) values obtained in the AP to BL direction showed CsA concentration (0.5 and 5.0 μM) dependence, whereas those of the reverse (BL to AP) process did not. Papp values for the AP to BL direction were also markedly lower. When the P-glycoprotein pump inhibitors, chlorpromazine and progesterone, were included in the transport medium we observed a significant increase in CsA (0.5 and 5.0 μM) transport from the AP to BL direction; transport was decreased in the reverse direction. This study suggests that CsA is transported across Caco-2 cells by passive diffusion, but that a polarized efflux system (presumably a P-glycoprotein pump) located at the apical membrane can attenuate the net AP to BL transport.
References (0)
Cited by (170)
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
2024, European Journal of Pharmaceutical SciencesThe upper airways represent the point of entrance from where Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection spreads to the lungs. In the present work, α-tocopheryl-polyethylene-glycol succinate (TPGS) micelles loaded with cyclosporine A (CSA) were developed for nasal administration to prevent or treat the viral infection in the very first phases. The behavior of the micelles in presence of simulated nasal mucus was investigated in terms of stability and mucopenetration rate, evidencing long-term stability and fast diffusion across the glycoproteins matrix. Moreover, the spray characteristics of the micellar formulation and deposition profile in a silicon nasal model were studied using three nasal spray devices. Results allowed to identify the nasal spray pump (BiVax, Aptar) able to provide the wider and uniform deposition of the nasal cavity. The cyclosporine A micelles antiviral activity against SARS-CoV-2 was tested on the Omicron BA.1 variant using Vero E6 cells with protocols simulating treatment before, during and after the infection of the upper airways. Complete viral inactivation was observed for the cyclosporine-loaded micelles while a very low activity was evidenced for the non-formulated drug, suggesting a synergistic activity of the drug and the formulation. In conclusion, this work showed that the developed cyclosporine A-loaded micellar formulations have the potential to be clinically effective against a wide spectrum of coronavirus variants.
Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review
2022, European Journal of Pharmaceutical SciencesThe absorption of orally administered drug products is a complex, dynamic process, dependant on a range of biopharmaceutical properties; notably the aqueous solubility of a molecule, stability within the gastrointestinal tract (GIT) and permeability. From a regulatory perspective, the concept of high intestinal permeability is intrinsically linked to the fraction of the oral dose absorbed. The relationship between permeability and the extent of absorption means that experimental models of permeability have regularly been used as a surrogate measure to estimate the fraction absorbed. Accurate assessment of a molecule's intestinal permeability is of critical importance during the pharmaceutical development process of oral drug products, and the current review provides a critique of in vivo, in vitro and ex vivo approaches. The usefulness of in silico models to predict drug permeability is also discussed and an overview of solvent systems used in permeability assessments is provided. Studies of drug absorption in humans are an indirect indicator of intestinal permeability, but both in vitro and ex vivo tools provide initial screening approaches and are important tools for assessment of permeability in drug development. Continued refinement of the accuracy of in silico approaches and their validation with human in vivo data will facilitate more efficient characterisation of permeability earlier in the drug development process and will provide useful inputs for integrated, end-to-end absorption modelling.
Design and synthesis of chemically modified peptides and proteins —critical considerations for oral delivery
2022, Oral Delivery of Therapeutic Peptides and ProteinsNaturally occurring polypeptides and proteins are recognized by digestive and circulatory enzymes which rapidly degrade and inactivate them. Even in the absence of degradation, the gastrointestinal tract presents a formidable physical barrier which precludes efficient absorption of all but the smallest oligopeptide fragments. In the event that assisted absorption can be effective, renal clearance from the systemic circulation quickly eliminates most unmodified peptides before they reach their target receptor. Here we discuss the barriers which exclude potential peptide therapeutics from peroral delivery and present some recent strategies in peptidomimetic design which have enabled just a handful of candidates to achieve regulatory approval by the oral route. The conclusion is that there are a specific set of physicochemical and biochemical properties which need to be fulfilled to achieve successful oral delivery of a peptide candidate and that meeting these criteria will not always be possible with all known endogenous peptides of interest.
Drug-drug interactions and their implications on the pharmacokinetics of the drugs
2022, Pharmacokinetics and Toxicokinetic Considerations - Vol IIPolypharmacy leads to increased incidences of drug–drug interactions (DDIs), which results in severe and debilitating drug-induced side effects. The potential DDI becomes significantly important with the gradual increase in age and the associated surge in multimorbidity and polypharmacy. Furthermore, an accurate method to predict the new DDI is necessary to circumvent the unknown adverse effects of the drug combinations. Hence, this chapter aims to discuss the impact of DDI on drug pharmacokinetics, and we further briefly discussed the critical role of microbiota in DDI. Furthermore, we reviewed the data on strategies to prevent the DDI and systematically presented it in the chapter. Finally, novel DDI prediction techniques and current clinical trial updates on DDI were discussed to predict the DDI in the least possible time with high accuracy.
Species differences in the drug–drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs
2020, European Journal of Pharmaceutical SciencesIn this study, drug-drug interaction (DDI) between atorvastatin (ATV) and cyclosporine (CsA) was kinetically analyzed using a stable isotope-IV method in rats and dogs. Obtained results were compared with the clinical data quoted from literatures to clarify the species difference in DDI both qualitatively and quantitatively. ATV only or ATV with CsA was orally administered to rats or dogs, and at 90 minutes after administration, a small amount of deuterium labeled ATV (ATV-d5) was intravenously injected. Assuming that ATV-d5 exhibits the same pharmacokinetic (PK) profile with ATV, PK parameters for absorption and elimination of ATV were calculated. Plasma levels of orally administered ATV were significantly enhanced by co-administration of CsA both in rats, dogs and humans, resulted in 9.8, 31, and 8.7-fold increase in systemic exposure calculated as AUCpo. High intensity of the DDI in dogs was mainly attributed to the marked decrease of the intrinsic hepatic clearance (to 1/10 of the control), which was induced by the inhibition of hepatic uptake of ATV via organic anion transporting polypeptide 1B1 (OATP1B1). CsA also affected the absorption of ATV form GI tract. Absorbed fraction of ATV into portal vein (calculated as Fa*Fg) was increased almost same extent in rats and dogs (around 3.0-fold) by co-administration of CsA. Inhibition of efflux transport via breast cancer resistance protein as well as the intestinal metabolism mediated by CYP enzymes contributed to the DDI occurred in the intestinal tract. In conclusion, PK analysis on the DDI between ATV and CsA in rats and dogs clearly demonstarted the factors to cause species differences in the extent of DDI. This type of quantitative analysis of DDIs in both small and large animals can be a great help to predict the extent of DDI in humans in the clinical study.
Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption
2019, International Journal of PharmaceuticsRecently, it has become evident that pharmaceutical excipients may interfere with the activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC). The present review aims to provide an overview of surfactants shown to modulate substrate transport via SLCs and ABCs, and to discuss the relevance for oral drug absorption. In vitro, more than hundred surfactants have been suggested to decrease the efflux activity of P-glycoprotein (P-gp, ABCB1), and many of these surfactants also inhibit the breast cancer resistance protein (BCPR, ABCG2), while conflicting results have been reported for multidrug resistance-associated protein 2 (MRP2, ABCC2). In animals, surfactants such as pluronic® P85 and polysorbate 20 have been shown to enhance the oral absorption of P-gp and BCRP substrates. Many surfactants, including cremophor® EL and Solutol® HS 15 inhibiting ABC transporters, were also found to inhibit SLCs in cell cultures. These carriers were SLC16A1, SLC21A3, SLC21A9, SLC15A1-2, and SLC22A1-3. This overlap in specificity of surfactants that inhibit both transporters and carriers might influence the oral absorption of various drug substances, nutrients, and vitamins. Such biopharmaceutical elements may be relevant for future drug formulation design.